Interview with Pawel Ciapala, Managing Director, Ipsen Poland
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
Address: 00-867 Warszawa
al. Jana Pawła II 29
Tel: 22 653 68 00
Web: http://www.ipsen.pl/
Ipsen is a global biopharmaceutical group, with sales exceeding 1 billion euros in 2009. The Group has total worldwide staff of more than 4,400 employees, of which nearly 900 contribute to the discovery and development of innovative drugs for patient care.
Ipsen’s research & development (R&D) centers and its peptide & protein engineering platform give the Group a strong competitive edge. In 2009, R&D expenditure totaled close to €200 million, representing nearly 20% of Group sales.
Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY.
Facts and figures in Poland:
Employment 30
Annual Turnover 80,000,000 zł.
Founded 1996
Ipsen’s development strategy is based on fast growing specialty care drugs in oncology, endocrinology, neurology and hematology, and on primary care drugs. This strategy is supported by an active policy of partnerships.
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
Merck’s managing director discusses the importance of diversification to succeed in Poland by saying: “Nowadays, in such a dynamic environment the healthy level of diversification that Merck offers is becoming…
Medtronic’s country director brings some interesting perspectives on the differences between the pharma and medical device regulations in Poland by saying: “the medical device industry is discriminated against, as we…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
Poland’s Main Pharmaceutical Inspector discusses the dangers behind falsified medicines and the need to control internet pharmacies. She also showcases the great power Poland holds as a manufacturing country with…
“In this very competitive environment, patents give companies an edge; this is why we must maintain innovative breakthroughs in our industry. This will then allow us to compete more efficiently…
“The overall Polish healthcare system is quite good. Of course, there are flaws, but Poland is equipped to treat almost any disease. The flaws in the system stem from historically…
In a world where diabetes increasingly more common, Poland has not been spared, with 2.5 million diabetic patients currently, and with a further 750,000 still unaware of their condition. In…
Cezary Sledziewski, Executive Director of PZPPF, discusses the pros and cons of Poland’s catching up with EU’s rising standards. He argues: “No one currently knows exactly how much these costs…
Polpharma , Poland’s role model and largest Polish manufacturer of drug products and active pharmaceutical ingredients, has pushed the Polish boundaries with the objective to become the fastest growing regional…
Poland has an important manufacturing role for the CEE region and this is where Mylan has settled Agila, a state-of-the-art, high quality injectables manufacturing platform. Mylan has great ambitions in…
See our Cookie Privacy Policy Here